Visium Asset Management
View Older Stories
-
10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025
-
10x Genomics (TXG) Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
-
10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2024 Results
-
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative
-
Canaccord Genuity Reiterates Buy Rating on 10X Genomics (TXG)
-
10x Genomics Reports Third Quarter 2024 Financial Results
-
10x Genomics Reports Second Quarter 2024 Financial Results
-
10x Genomics Reports First Quarter 2024 Financial Results
-
10x Genomics (TXG) Commercially Launches Visium HD Spatial Gene Expression Assay
-
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
-
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
-
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
-
10x Genomics (TXG) Announces Preliminary Fourth Quarter and Full Year 2023 Results
-
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
-
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
-
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
-
OWKIN Integrates 10x Genomics (TXG) Spatial Omics and Single-Cell Technologies to the MOSAIC Study
-
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
-
10x Genomics Reports Third Quarter 2023 Financial Results
-
Study Enabled by 10x Genomics Single Cell and Spatial Technologies Explains Why Immunotherapy is More Effective for Certain Brain Tumors Than Others
-
10x Genomics Reports Second Quarter 2023 Financial Results
-
10x Genomics (TXG) Launches Visium CytAssist Gene and Protein Expression Assay
-
10x Genomics Launches Visium CytAssist Gene and Protein Expression Assay
-
10x Genomics Reports First Quarter 2023 Financial Results
-
10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023
-
10x Genomics Demonstrates Breadth, Scale and Leadership at 2023 AGBT General Meeting
-
10x Genomics Commercially Launches Xenium Platform for In Situ Analysis
-
10x Genomics Reports Third Quarter 2022 Financial Results
-
UPDATE: Goldman Sachs Downgrades 10X Genomics (TXG) to Sell
-
10x Genomics Reports Second Quarter 2022 Financial Results
-
10x Genomics Advances Leadership and Innovation in Single Cell and Spatial Technologies at 2022 AGBT General Meeting
-
10x Genomics Reports First Quarter 2022 Financial Results
-
10x Genomics Launches Two New Products to Unlock Wider Range of Samples for Single Cell Analysis on Chromium
-
10x Genomics Showcases Robust Innovation Pipeline at Xperience 2022 Event
-
10x Genomics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Outlook for 2022
-
10x Genomics Recognized on The Scientist's Top 10 Innovations List for Fifth Consecutive Year
-
10x Genomics Reports Second Quarter 2021 Financial Results
-
10x Genomics Reports Second Quarter 2021 Financial Results
-
10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping
-
10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping
-
10x Genomics (TXG) Tops Q1 EPS by 16c, Revenues Beat; Offers FY21 Revenues Mid-Point Guidance Below Consensus
-
10x Genomics Reports First Quarter 2021 Financial Results
-
10x Genomics Reports First Quarter 2021 Financial Results
-
10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event
-
10x Genomics Showcases Next Wave of Innovations at First Ever Xperience Event
-
10x Genomics (TXG) Signs Agreement to Acquire ReadCoor; Acquires Sweden’s CartaNA AB
-
10x Genomics Advances into Emerging Field of In Situ Analysis with Two Acquisitions
-
10x Genomics Advances into Emerging Field of In Situ Analysis with Two Acquisitions
-
10x Genomics First to Market With Product to Simultaneously Capture Epigenome and Transcriptome
-
10x Genomics First to Market With Product to Simultaneously Capture Epigenome and Transcriptome

